Imaging Core

成像核心的主题是人类乳腺癌小鼠模型的分子成像。 Core为各个项目提供了基于非侵入性定量成像的功能， 肿瘤及其微环境的代谢和遗传特征，包括体内 肿瘤细胞的运输。这将通过监测“直接靶向”探针和 使用光学（生物发光和生物荧光）的单模态和多模态报告基因的表达 放射性核素（PET、SPECT和放射自显影）、MRI/MRS、CT和US）成像。 这些定量、非侵入性成像技术在MSKCC已为小动物和 和患者成像研究。它们是定量和非侵入性的，因此易于适应 纵向研究。成像核心可以容易地提供[18F]-FDG、[18F]-FLT、[18F]-ACBC和[18F]-FDG。 对所有RP进行[I8 F]-FMISO或[124 I]-IAZG microPET，用于肿瘤糖酵解、细胞 增殖、氨基转运和缺氧。此外，A 用于小动物体内非侵入性成像的许多诱导型报告系统已经 开发这些报告器系统都是多模态报告器，并且包括以下功能： 荧光、生物发光和放射性核素成像。除了p53和DFHR， 诱导型报告基因包括NFAT，FIRE（缺氧反应元件-缺氧诱导因子），E2 F， 叉头因子（FOXO）、热休克蛋白70（HSP 70）和TGF β。一般的两步战略是 通常在探针开发中追求：首先，建立和验证成像和非侵入性测定 第二，在适当的情况下，翻译我们的选择方面， 在本研究中提出的研究项目（RP）的背景下， 应用程序.成像核心将积极和直接支持所有五个RP，由哈罗德瓦姆斯领导， 琼·马萨格，尼尔罗森，玛丽亚·贾辛和罗伯特·贝内兹拉。

The theme of the Imaging Core is molecular imaging of mouse models of human breast cancer. The Core provides individual projects with non-invasive, quantitative imaging-based capabilities for metabolic and genetic characterization of tumors and their microenvironment, including in vivo trafficking of tumor cells. This will be accomplished by monitoring of "directly-targeting" probes and of the expression of single and multi-modality reporter genes using optical (bioluminescence and fluorescence), radionuclide (PET, SPECT, and autoradiography), MRI/MRS, CT, and US) imaging. These quantitative, non-invasive imaging techniques are well-established at MSKCC for both smallanimal and patient imaging studies. They are quantitative and non-invasive and thus readily adaptable to longitudinal studies. The Imaging Core can readily provide [18F]-FDG, [18F]-FLT, [18F]-ACBC , and [I8F]-FMISO or [124I]-IAZG microPET to all RPs for non-invasive assessment of tumor glycolysis, cell proliferation, amino transport, and hypoxia, respectively, in mouse models of breast cancer. Further, a number of inducible reporter systems for non-invasive in vivo imaging in small animals have been developed. These reporter systems are all multi-modality reporters and include the capability for fluorescence, bioluminescence and radionuclide imaging. In addition to p53 and DFHR, the list of inducible reporters includes NFAT, FIRE (hypoxia response element - hypoxia inducible factor), E2F, Forkhead factor (FOXO), heat shock protein 70 (HSP70) and TGFp. A general two-step strategy is generally pursued in probe development: first, to establish and validate imaging and non-invasive assay techniques in experimental animals, and second, to translate where appropriate selected aspects of our imaging technology to patient studies within the context of the Research Projects (RPs) proposed in this Application. The Imaging Core will actively and directly support all five RPs, led by Harold Varmus, Joan Massague, Neil Rosen, Maria Jasin, and Robert Benezra, respectively.